X

Trial Profile

Phase I trial to evaluate the safety and efficacy of tetracosactide patients with Duchenne muscular dystrophy

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Sep 2016

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tetracosactide (Primary)
Indications Duchenne muscular dystrophy
Focus Adverse reactions

Most Recent Events

18 Sep 2016 New trial record
25 Aug 2016 According to Mallinckrodt media release, first patient of the trial was dosed in August 2016.
25 Aug 2016 In August 2016, US FDA granted a fast-track designation to Mallinckrodt for its IND application for Synacthen Depot in the treatment of duchenne muscular dystrophy, according to Mallinckrodt media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com